Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01864356 · ClinicalTrials.gov registry record · Phase 2
A Multi-Center Study To Evaluate Multiple Doses of NT100 Following IVF In Women With Repeated IVF Failures (Thrive-IVF)
A Phase 2 study of Repeated IVF Failure, sponsored by Nora Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 157
- Enrollment target
- 20
- Study locations
NCT01864356 is a Phase 2 study of Repeated IVF Failure that has completed, run by Nora Therapeutics. The registered enrollment target is 157 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT01864356, a Phase 2 study of Repeated IVF Failure, has completed, sponsored by Nora Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 157 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of multiple doses of subcutaneous NT100 vs placebo following in vitro fertilization (IVF) in women with a history of repeated IVF failures.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NT100
Study Locations (20)
California
- HRC Fertility - Encino
- HRC Fertility - Newport Beach
- HRC Fertility - Pasadena
- UCSF - San Francisco
Texas
- Center for Assisted Reproduction - Bedford
- Houston Fertility Institute - Houston
- Center of Reproductive Medicine - Webster
Florida
- Florida Fertility Institute - Clearwater
- IVF and Fertility Center of Miami - Miami
Illinois
- Fertility Centers of Illinois / River North IVF Center - Chicago
- Fertility Centers of Illinois / Highland Park IVF Center - Highland Park
Massachusetts
- Brigham and Women's Hospital - Boston
- Boston IVF - Waltham
Delaware
- Reproductive Associates of Delaware - Newark
District of Columbia
- Columbia Fertility Associates - Washington D.C.
Georgia
- Georgia Reproductive Specialists - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01864356
The ClinicalTrials.gov registry entry for NCT01864356 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nora Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Repeated IVF Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01864356 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT01864356 about?
NCT01864356 is a clinical study titled "A Multi-Center Study To Evaluate Multiple Doses of NT100 Following IVF In Women With Repeated IVF Failures (Thrive-IVF)". The purpose of this study is to evaluate the efficacy, safety and tolerability of multiple doses of subcutaneous NT100 vs placebo following in vitro fertilization (IVF) in women with a history of repeated IVF failures.
What is the current status of trial NCT01864356?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2013-05. Estimated completion is 2014-09.
What conditions does trial NCT01864356 study?
This clinical trial studies the following conditions: Repeated IVF Failure.
What interventions are being tested in trial NCT01864356?
The interventions under investigation include: Placebo (DRUG), NT100 (DRUG).
Who is sponsoring clinical trial NCT01864356?
This trial is sponsored by Nora Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01864356 being conducted?
This trial has 20 study locations across California, Delaware, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.